https://www.selleckchem.com/products/arry-380-ont-380.html BACKGROUND We examined the protective effects of the natural flavonoid, quercetin, against cerebral vasospasm in an experimental rat subarachnoid haemorrhage (SAH) model. MATERIALS AND METHODS Thirty-eight albino Wistar rats were divided into five groups as follows group 1 (G1, n=8), no experimental intervention; group 2 (G2, n=8), subarachnoid physiological saline; group 3 (G3, n=8), SAH; group 4 (G4, n=7) SAH and low-dose (10 mg/kg) quercetin treatment; group 5 (G5, n=7), SAH and high-dose (50 mg/kg) quercetin treatment. Subarachnoid haemorrhage was induced by injection of 0.15 cc of autologous blood taken from the tail artery into the cisterna magna from the craniocervical junction and basilar arteries and blood samples were taken for biochemical and histopathological analyses. RESULTS Malondialdehyde (MDA) levels were significantly higher in G2 and G3 than in G1 (p0.05). There were no significant differences in BA wall thickness between G3 and G4 or between G3 and G5, but G4 and G5 showed greater luminal diameters than G3 (p less then 0.05). There were no significant differences in BA thickness or luminal diameter between G4 and G5. CONCLUSION Our results suggested that quercetin may be beneficial in SAH therapy by preventing vasospasm.BACKGROUND Oral corticosteroid (OCS) dependent severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps (SEA-CRSwNP) would be a suitable phenotype for mepolizumab treatment. OBJECTIVE To evaluate the short-term efficacy of mepolizumab treatment on the OCS dependant SEA-CRSwNP Methods Baseline and 24th-week results [daily OCS doses, asthma exacerbation frequency, asthma control test(ACT) scores, blood eosinophil levels, FEV1 values and numerical analog scale (NAS) of CRSwNP symptoms] of the patients that were treated at least 24 week with mepolizumab were retrospectively evaluated and compared. #link# RESULTS A total of 16 patients were enrolled in the study